Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Drugs in R&D·2026
Same journal

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.

Drugs in R&D·2026
Same journal

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

Drugs in R&D·2026
Same journal

Ustekinumab in the Management of Perianal Fistulizing Crohn's Disease: Current Evidence and Practical Strategies.

Drugs in R&D·2026
Same journal

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.

Drugs in R&D·2026
Same journal

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.

Drugs in R&D·2026

Related Experiment Video

Updated: Jun 8, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Ridaforolimus

    Drugs in R&D
    |October 16, 2010
    PubMed
    Summary
    This summary is machine-generated.

    Ridaforolimus, an mTOR inhibitor, shows promise in treating various cancers, including sarcomas, breast, endometrial, lung, and prostate cancers. Clinical trials are evaluating its efficacy and development milestones for these conditions.

    More Related Videos

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
    08:47

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

    Published on: May 1, 2020

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
    10:38

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

    Published on: December 16, 2022

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
    08:38

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

    Published on: November 8, 2015

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
    08:47

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

    Published on: May 1, 2020

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
    10:38

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

    Published on: December 16, 2022

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Ridaforolimus (AP23573; MK 8669) is a sirolimus analog and a small molecule inhibitor of the mammalian target of rapamycin (mTOR).
    • It is being investigated for its potential in cancer treatment.

    Purpose of the Study:

    • To review the key development milestones of Ridaforolimus.
    • To discuss the therapeutic trials involving Ridaforolimus for various cancer types.

    Main Methods:

    • Review of clinical trial data and development milestones.
    • Analysis of Ridaforolimus's efficacy in different cancer indications.

    Main Results:

    • Ridaforolimus is in Phase III development for soft-tissue and bone sarcomas in the EU and US.
    • Phase II trials are ongoing for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer.

    Conclusions:

    • Ridaforolimus demonstrates potential as a therapeutic agent across a spectrum of cancers.
    • Further clinical evaluation is ongoing to establish its role in cancer treatment regimens.